Lantheus Announces Leadership Transition Plan

Brian Markison to Retire as Chief Executive Officer; Board Conducting Search for Next CEO 

Continued Execution of Company’s Strategy to be Led by Prior CEO Mary Anne Heino as Executive Chairperson

BEDFORD, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that Chief Executive Officer Brian Markison will retire from the Company, effective December 31, 2025, after more than 13 years of service to Lantheus as director and executive. The Board has initiated a comprehensive search process to help identify a new CEO. To support an orderly and seamless transition, Mr. Markison has agreed to serve as a strategic advisor to the Company through at least March 31, 2026.

Mary Anne Heino, who currently serves as Chairperson of the Board of Directors and previously served as Lantheus CEO from 2015 to 2024, has been appointed Executive Chairperson, effective November 7, 2025. Following Mr. Markison’s retirement at the end of the year, Ms. Heino will lead the company as interim CEO until the Company’s next CEO is appointed.

Separately, Lantheus announced today that its President, Paul Blanchfield, has accepted a role at another company and is leaving Lantheus. Ms. Heino and Mr. Markison will work together to assume Mr. Blanchfield’s responsibilities. In addition, Amanda Morgan will return from leave and continue in her role as Chief Commercial Officer, reporting directly to Ms. Heino.

“On behalf of the Board, I want to express our sincere gratitude to Brian for his leadership and dedication to Lantheus,” said Julie McHugh, Lead Independent Director. “His valuable insights and contributions strengthened Lantheus’ leadership position at the forefront of radiopharmaceutical innovation and have positioned the Company for future growth opportunities with multiple near-term potential FDA market approvals and a strong pipeline of diagnostic and therapeutic candidates. I also want to thank Paul for his contributions to Lantheus over the years and wish him well in his future endeavors.”